








# SHARED DECISION-MAKING TOOL FOR CHOOSING A GLP-1 RECEPTOR AGONIST\*

This summary table is designed to help you discuss available GLP-1 RA options with your patients. It is based on published clinical trials and prescribing information.

	Subcutaneous Injection					Oral	
Generic Name	Exenatide	Liraglutide	Exenatide LAR		Dulaglutide	Semaglutide	Semaglutide
Brand Name	Byetta	Victoza	Bydureon	Bydureon BCise	Trulicity	Ozempic	Rybelsus
Photo							
Frequency	Twice a day: before breakfast and dinner, within 60 min of each meal, ~6h apart	Once a day: any time and independent of meals, but establish a routine and take at same time daily	Once a week		Once a week	Once a week	Once a day: 30 min before food, beverages, and other meds. Take with no more than 4 oz of water
Approved doses	5 µg 10 µg	1.2 mg 1.8 mg	2 mg		0.75 mg 1.5 mg	0.5 mg 1.0 mg	7 mg 14 mg
Injection device comfort/ease	+	++	+		+++	++	N/A
Needle size (gauge/mm)	29, 30, or 31 gauge, 4 mm needle. Discuss with provider which is best.	32-gauge, NovoFine (6 mm needle) or NovoFine Plus. 4 mm needle also available.	23-gauge, 8 mm or 23-gauge, 7 mm (BCise single-dose autoinjector)		29-gauge, 5 mm	32-gauge, 4 mm	N/A
Needles included?	No	No	Yes		Yes (part of device and needle is hidden)	Yes	N/A
Injection site reaction	If they occur, most often transient, and generally do not cause discontinuation.						N/A

## SHARED DECISION-MAKING TOOL FOR CHOOSING A GLP-1 RECEPTOR AGONIST\* (cont'd)

	Subcutaneous Injection					Oral
Generic Name	Exenatide	Liraglutide	Exenatide LAR	Dulaglutide	Semaglutide	Semaglutide
Reconstitution or Mixing	No	No	Yes	No	No	N/A
Storage	Keep refrigerated prior to initial use; after first use may store at room temp	Keep refrigerated prior to initial use; after first use may store at room temp	Single-dose dual pen: Keep refrigerated prior to initial use; after first use may store at room temp  Single-dose autoinjector: Keep refrigerated. If needed, may store at room temp for up to 4 weeks	Keep refrigerated; if needed, may store at room temp for 14 days	Keep refrigerated prior to initial use; after first use may store at room temp	Store in a dry place; keep tablets in original blister pack until ready for use
Dose adjustment (titration)	Yes	Yes	No	No	Yes	Yes
Weight loss (lbs)	2.9	5.7-6.2	5.0	5.3-6.4	10.1-14.3	8.3
A1C reduction (% reduction as add on to metformin)	0.5-0.9	1.0	1.6	0.7-1.4	1.0-1.8	1.0-1.3
FPG reduction, (mg/dL)	5.4-28.8	15.1-44.0	31.1-47.0	26.0-43.0	35.0-43.0	36
PPG reduction, (mg/dL)	30.0-52.2	29.0-49.0	Not Reported (NR)	41.4-46.1	NR	NR
CV benefit		Yes		Yes	Yes	
Hypoglycemia	No	No	No	No	No	No
Renal benefit		+		+	+	+
Nausea/vomiting	Usually transient. Decrease portion sizes and fat content of meals.					
Cost/insurance coverage	Options should be addressed in context of patient's insurance coverage and/or ability to pay.					

\*This document is not a substitute for individual clinical judgment. Practicing Clinicians Exchange recommends information contained herein be checked against published guidelines, peer-reviewed literature, and product information/package inserts.

### Notes:

---



---



---



---

# SHARED DECISION-MAKING TOOL FOR CHOOSING A GLP-1 RECEPTOR AGONIST\* (cont'd)

## References

1. American Diabetes Association. Standards of medical care in diabetes - 2020. *Diabetes Care*. 2020;43(Suppl 1):S1-S212.
2. Bethel MA, Patel RA, Merrill P, et al. Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: A meta-analysis. *Lancet Diabetes Endocrinol*. 2018;6:105-113.
3. Bydureon (exenatide extended-release) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2017.
4. Bydureon BCISE (exenatide extended-release) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2017.
5. Byetta (exenatide) [prescribing information]. San Diego, CA: Amylin Pharmaceuticals, Inc.; 2018.
6. Cosentino F, Grant PJ, Aboyans V, et al. 2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. *Eur Heart J*. 2020;41:255-323.
7. Filippatos TD, Panagiotopoulou TV, Elisaf MS. Adverse effects of GLP-1 receptor agonists. *Rev Diabet Stud*. 2014;11:202-230.
8. Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): A double-blind, randomised placebo-controlled trial. *Lancet*. 2019;394:121-130.
9. Holman RR, Bethel MA, Mentz RJ, et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. *N Engl J Med*. 2017;377:1228-1239.
10. Husain M, Birkenfeld AL, Donsmark M, et al. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. *N Engl J Med*. 2019;381:841-851.
11. Iglay K, Hannachi H, Joseph Howie P, et al. Prevalence and co-prevalence of comorbidities among patients with type 2 diabetes mellitus. *Curr Med Res Opin*. 2016;32:1243-1252.
12. Kruger DF, Bode B, Spollett GR. Understanding GLP-1 analogs and enhancing patients success. *Diabetes Educ*. 2010;36 Suppl 3:44S-72S; quiz 73S-74S.
13. Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. *N Engl J Med*. 2016;375:1834-1844.
14. Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. *N Engl J Med*. 2016;375:311-322.
15. Monami M, Nreu B, Scatena A, et al. Safety issues with glucagon-like peptide-1 receptor agonists (pancreatitis, pancreatic cancer and cholelithiasis): Data from randomized controlled trials. *Diabetes Obes Metab*. 2017;19:1233-1241.
16. Nauck MA, Meier JJ. Are all GLP-1 agonists equal in the treatment of type 2 diabetes? *Eur J Endocrinol*. 2019;181:R2110-R234.
17. Ozempic (semaglutide) [prescribing information]. Bagsvaerd, Denmark: Novo Nordisk A/S; 2020.
18. Rybelsus (semaglutide) [prescribing information]. Plainsboro, NJ: Novo Nordisk, Inc; 2020.
19. Santos Cavaiola T, Kiriakov Y, Reid T. Primary care management of patients with type 2 diabetes: Overcoming inertia and advancing therapy with the use of injectables. *Clin Ther*. 2019;41:352-367.
20. Trulicity (dulaglutide) [prescribing information]. Indianapolis, IN: Eli Lilly and Company; 2020.
21. Victoza (liraglutide) [prescribing information]. Plainsboro, NJ: Novo Nordisk A/S; 2019.